Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells

1 The desensitizing acetylcholine (ACh) response of bovine chromaffin cells maintained in culture was examined using rapid agonist applications (of 2 s duration) which imposed nominal drug concentrations within 50 ms. This study was aimed, firstly, at identifying which of the α3, α4 and α7 subunits...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 1995-02, Vol.114 (3), p.648-655
Hauptverfasser: Nooney, J.M., Feltz, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 655
container_issue 3
container_start_page 648
container_title British journal of pharmacology
container_volume 114
creator Nooney, J.M.
Feltz, A.
description 1 The desensitizing acetylcholine (ACh) response of bovine chromaffin cells maintained in culture was examined using rapid agonist applications (of 2 s duration) which imposed nominal drug concentrations within 50 ms. This study was aimed, firstly, at identifying which of the α3, α4 and α7 subunits known to be present in these cells is predominant in the ACh‐evoked response and secondly, on the effects on these neuronal nicotinic ACh receptors (AChR) of cyclothiazide (CT), an agent acting as a modulator of a gating desensitization site on other ligand‐gated channels. 2 Locally applied 100 μm ACh evoked peak currents (IAch) of −1.5 ± 0.1 nA (n = 83) at a holding potential of −60 mV. The ACh dose‐response curve yielded an estimated EC50 of 60 μm. This current was not sustained but desensitized during the application period; it displayed strong inward rectification, but desensitized equally whether the evoked current was inward or outward going. The latter observation excludes α4 as a major contributor to the recorded current. Because the response was almost insensitive to a 1 μm α‐bungarotoxin pretreatment (IACg = −12 ± 0.1 nA; n = 6), and because 1, 1‐dimethyl‐4‐phenylpiperazinium (DMPP) works as a potent agonist (peak current = −1.9 nA, n = 2 for 100 μm DMPP), the α7 subunit is also a minor contributor to the response. Taken together, these observations suggest a dominant α3 type of response. 3 Triple exponential fits were used to describe the characteristics of the ACh‐evoked currents; one component to fit the rising phase, with 2 components to describe the decay phase. The decay times were 100 ms and 4 s for the fast and slow components respectively. The rate of the slow decay component increased systematically with recording time, approximately doubling from its initial value within 20–40 min. Furthermore there was a gradual rundown of the response, seen first as a loss of the late component of the current, measured at 2 s, with the peak current amplitude decreasing later in the recording. 4 CT, when coapplied with ACh, produced a dose‐dependent inhibition of the ACh‐evoked peak current. The effect showed little voltage‐dependency with 100 μm CT producing 46 ± 5% (s.d.; n = 3) and 47 ± 8% (s.d.; n = 7) inhibition at −100 and −60 mV respectively. At +60 mV, inhibition was estimated to be 26 ± 7% (s.d.; n = 3). 5 After pre‐exposure of the cells to CT by bath application, 10 and 30 μm CT produced poorly reversible 20 ± 9% (n = 7) and 42 ± 5% (n = 4) inhibi
doi_str_mv 10.1111/j.1476-5381.1995.tb17188.x
format Article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1510031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BPH17188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5078-a3befac735ad43a0a18552885babadd7eb8a5928b9370e5eebcc615f96eef8013</originalsourceid><addsrcrecordid>eNqVkE1PHCEYx4mpsVvbj2AyMb3OCLIMjIemrWmriYke2l7JA_PQZTMLGxit66cv091s9CgHIPxfePIj5JTRhpV1tmzYXLa14Io1rOtEMxommVLN4wGZ7aU3ZEYplTUrylvyLuclpUWU4ogcSclF27EZ-X0dFt740cdQmU1lN3aI48LDk--xiq4KeJ9igKEK3sbRl71KmNcxZMyVL5n44ANWdpHiCpwrLxaHIb8nhw6GjB925zH59f3bz8ur-ub2x_Xll5vaCipVDdygA1uGgX7OgQJTQpwrJQwY6HuJRoHozpXpuKQoEI21LROuaxGdoowfk0_b3vW9WWFvMYwJBr1OfgVpoyN4_VIJfqH_xAfNBKOUTwUX2wKbYs4J3T7LqJ5g66WeiOqJqJ5g6x1s_VjCJ89_30d3dIv-cadDtjC4BMH6vLfxOWNtJ4rt89b21w-4ecUA-uvd1f8r_wc2_aCB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Nooney, J.M. ; Feltz, A.</creator><creatorcontrib>Nooney, J.M. ; Feltz, A.</creatorcontrib><description>1 The desensitizing acetylcholine (ACh) response of bovine chromaffin cells maintained in culture was examined using rapid agonist applications (of 2 s duration) which imposed nominal drug concentrations within 50 ms. This study was aimed, firstly, at identifying which of the α3, α4 and α7 subunits known to be present in these cells is predominant in the ACh‐evoked response and secondly, on the effects on these neuronal nicotinic ACh receptors (AChR) of cyclothiazide (CT), an agent acting as a modulator of a gating desensitization site on other ligand‐gated channels. 2 Locally applied 100 μm ACh evoked peak currents (IAch) of −1.5 ± 0.1 nA (n = 83) at a holding potential of −60 mV. The ACh dose‐response curve yielded an estimated EC50 of 60 μm. This current was not sustained but desensitized during the application period; it displayed strong inward rectification, but desensitized equally whether the evoked current was inward or outward going. The latter observation excludes α4 as a major contributor to the recorded current. Because the response was almost insensitive to a 1 μm α‐bungarotoxin pretreatment (IACg = −12 ± 0.1 nA; n = 6), and because 1, 1‐dimethyl‐4‐phenylpiperazinium (DMPP) works as a potent agonist (peak current = −1.9 nA, n = 2 for 100 μm DMPP), the α7 subunit is also a minor contributor to the response. Taken together, these observations suggest a dominant α3 type of response. 3 Triple exponential fits were used to describe the characteristics of the ACh‐evoked currents; one component to fit the rising phase, with 2 components to describe the decay phase. The decay times were 100 ms and 4 s for the fast and slow components respectively. The rate of the slow decay component increased systematically with recording time, approximately doubling from its initial value within 20–40 min. Furthermore there was a gradual rundown of the response, seen first as a loss of the late component of the current, measured at 2 s, with the peak current amplitude decreasing later in the recording. 4 CT, when coapplied with ACh, produced a dose‐dependent inhibition of the ACh‐evoked peak current. The effect showed little voltage‐dependency with 100 μm CT producing 46 ± 5% (s.d.; n = 3) and 47 ± 8% (s.d.; n = 7) inhibition at −100 and −60 mV respectively. At +60 mV, inhibition was estimated to be 26 ± 7% (s.d.; n = 3). 5 After pre‐exposure of the cells to CT by bath application, 10 and 30 μm CT produced poorly reversible 20 ± 9% (n = 7) and 42 ± 5% (n = 4) inhibitions of the peak current respectively. There were no discernible effects on the fitted decay constants at any CT concentration tested, although an increased inhibitory effect of CT was observed at higher concentrations (100 μm) on the amplitude of the late component measured at 2 s. 6 Similar effects were observed in conditions chosen to isolate the α3 type of receptor: namely when using DMPP as an agonist, or after α‐bungarotoxin pretreatment. 7 The 2,3‐benzodiazepine, GYKI 53655, is known to antagonize the action of CT on AMPA receptors. Coapplication of 50 μm GYKI 53655 with ACh (100 μm) produced a 29 ± 4% inhibition of the peak ACh‐evoked current and 44 ± 6% inhibition of its amplitude at 2 s (n = 4). This response was fully reversible. Brief applications of both CT (100 μm) and GYKI 53655 (50 μm) with ACh via the microperfusion system produced a fully reversible inhibition that was not significantly different from the values obtained with either CT or GYKI 53655 alone, with 37 ± 6% inhibition of peak and 61 ± 9% inhibition of the amplitude at 2 s (n = 3). 8 The results obtained suggest that the CT effect is to impede recovery from a slow desensitization, with a more pronounced effect with longer CT applications. Globally, CT favours the ‘rundown state’ of the neuronal nicotinic AChR.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/j.1476-5381.1995.tb17188.x</identifier><identifier>PMID: 7735691</identifier><identifier>CODEN: BJPCBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Acetylcholine - pharmacology ; Animals ; Antihypertensive agents ; Antihypertensive Agents - pharmacology ; Benzodiazepines - pharmacology ; Benzothiadiazines - pharmacology ; Biological and medical sciences ; Bungarotoxins - pharmacology ; Cardiovascular system ; Cattle ; Cells, Cultured ; chromaffin cells ; Chromaffin System - cytology ; Chromaffin System - drug effects ; Chromaffin System - metabolism ; Cyclothiazide ; desensitization ; Dimethylphenylpiperazinium Iodide - pharmacology ; Diuretics ; Dose-Response Relationship, Drug ; Drug Interactions ; Drug Synergism ; GYKI 53655 ; Medical sciences ; Neurons - cytology ; Neurons - drug effects ; Neurons - metabolism ; Nicotinic Antagonists ; nicotinic receptor ; Pharmacology. Drug treatments ; Receptors, AMPA - drug effects ; Receptors, AMPA - metabolism ; Receptors, Nicotinic - drug effects ; Receptors, Nicotinic - metabolism ; Sodium Chloride Symporter Inhibitors - pharmacology ; α‐bungarotoxin</subject><ispartof>British journal of pharmacology, 1995-02, Vol.114 (3), p.648-655</ispartof><rights>1995 British Pharmacological Society</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5078-a3befac735ad43a0a18552885babadd7eb8a5928b9370e5eebcc615f96eef8013</citedby><cites>FETCH-LOGICAL-c5078-a3befac735ad43a0a18552885babadd7eb8a5928b9370e5eebcc615f96eef8013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510031/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510031/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3411695$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7735691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nooney, J.M.</creatorcontrib><creatorcontrib>Feltz, A.</creatorcontrib><title>Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>1 The desensitizing acetylcholine (ACh) response of bovine chromaffin cells maintained in culture was examined using rapid agonist applications (of 2 s duration) which imposed nominal drug concentrations within 50 ms. This study was aimed, firstly, at identifying which of the α3, α4 and α7 subunits known to be present in these cells is predominant in the ACh‐evoked response and secondly, on the effects on these neuronal nicotinic ACh receptors (AChR) of cyclothiazide (CT), an agent acting as a modulator of a gating desensitization site on other ligand‐gated channels. 2 Locally applied 100 μm ACh evoked peak currents (IAch) of −1.5 ± 0.1 nA (n = 83) at a holding potential of −60 mV. The ACh dose‐response curve yielded an estimated EC50 of 60 μm. This current was not sustained but desensitized during the application period; it displayed strong inward rectification, but desensitized equally whether the evoked current was inward or outward going. The latter observation excludes α4 as a major contributor to the recorded current. Because the response was almost insensitive to a 1 μm α‐bungarotoxin pretreatment (IACg = −12 ± 0.1 nA; n = 6), and because 1, 1‐dimethyl‐4‐phenylpiperazinium (DMPP) works as a potent agonist (peak current = −1.9 nA, n = 2 for 100 μm DMPP), the α7 subunit is also a minor contributor to the response. Taken together, these observations suggest a dominant α3 type of response. 3 Triple exponential fits were used to describe the characteristics of the ACh‐evoked currents; one component to fit the rising phase, with 2 components to describe the decay phase. The decay times were 100 ms and 4 s for the fast and slow components respectively. The rate of the slow decay component increased systematically with recording time, approximately doubling from its initial value within 20–40 min. Furthermore there was a gradual rundown of the response, seen first as a loss of the late component of the current, measured at 2 s, with the peak current amplitude decreasing later in the recording. 4 CT, when coapplied with ACh, produced a dose‐dependent inhibition of the ACh‐evoked peak current. The effect showed little voltage‐dependency with 100 μm CT producing 46 ± 5% (s.d.; n = 3) and 47 ± 8% (s.d.; n = 7) inhibition at −100 and −60 mV respectively. At +60 mV, inhibition was estimated to be 26 ± 7% (s.d.; n = 3). 5 After pre‐exposure of the cells to CT by bath application, 10 and 30 μm CT produced poorly reversible 20 ± 9% (n = 7) and 42 ± 5% (n = 4) inhibitions of the peak current respectively. There were no discernible effects on the fitted decay constants at any CT concentration tested, although an increased inhibitory effect of CT was observed at higher concentrations (100 μm) on the amplitude of the late component measured at 2 s. 6 Similar effects were observed in conditions chosen to isolate the α3 type of receptor: namely when using DMPP as an agonist, or after α‐bungarotoxin pretreatment. 7 The 2,3‐benzodiazepine, GYKI 53655, is known to antagonize the action of CT on AMPA receptors. Coapplication of 50 μm GYKI 53655 with ACh (100 μm) produced a 29 ± 4% inhibition of the peak ACh‐evoked current and 44 ± 6% inhibition of its amplitude at 2 s (n = 4). This response was fully reversible. Brief applications of both CT (100 μm) and GYKI 53655 (50 μm) with ACh via the microperfusion system produced a fully reversible inhibition that was not significantly different from the values obtained with either CT or GYKI 53655 alone, with 37 ± 6% inhibition of peak and 61 ± 9% inhibition of the amplitude at 2 s (n = 3). 8 The results obtained suggest that the CT effect is to impede recovery from a slow desensitization, with a more pronounced effect with longer CT applications. Globally, CT favours the ‘rundown state’ of the neuronal nicotinic AChR.</description><subject>Acetylcholine - pharmacology</subject><subject>Animals</subject><subject>Antihypertensive agents</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Benzodiazepines - pharmacology</subject><subject>Benzothiadiazines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Bungarotoxins - pharmacology</subject><subject>Cardiovascular system</subject><subject>Cattle</subject><subject>Cells, Cultured</subject><subject>chromaffin cells</subject><subject>Chromaffin System - cytology</subject><subject>Chromaffin System - drug effects</subject><subject>Chromaffin System - metabolism</subject><subject>Cyclothiazide</subject><subject>desensitization</subject><subject>Dimethylphenylpiperazinium Iodide - pharmacology</subject><subject>Diuretics</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Interactions</subject><subject>Drug Synergism</subject><subject>GYKI 53655</subject><subject>Medical sciences</subject><subject>Neurons - cytology</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Nicotinic Antagonists</subject><subject>nicotinic receptor</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, AMPA - drug effects</subject><subject>Receptors, AMPA - metabolism</subject><subject>Receptors, Nicotinic - drug effects</subject><subject>Receptors, Nicotinic - metabolism</subject><subject>Sodium Chloride Symporter Inhibitors - pharmacology</subject><subject>α‐bungarotoxin</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkE1PHCEYx4mpsVvbj2AyMb3OCLIMjIemrWmriYke2l7JA_PQZTMLGxit66cv091s9CgHIPxfePIj5JTRhpV1tmzYXLa14Io1rOtEMxommVLN4wGZ7aU3ZEYplTUrylvyLuclpUWU4ogcSclF27EZ-X0dFt740cdQmU1lN3aI48LDk--xiq4KeJ9igKEK3sbRl71KmNcxZMyVL5n44ANWdpHiCpwrLxaHIb8nhw6GjB925zH59f3bz8ur-ub2x_Xll5vaCipVDdygA1uGgX7OgQJTQpwrJQwY6HuJRoHozpXpuKQoEI21LROuaxGdoowfk0_b3vW9WWFvMYwJBr1OfgVpoyN4_VIJfqH_xAfNBKOUTwUX2wKbYs4J3T7LqJ5g66WeiOqJqJ5g6x1s_VjCJ89_30d3dIv-cadDtjC4BMH6vLfxOWNtJ4rt89b21w-4ecUA-uvd1f8r_wc2_aCB</recordid><startdate>199502</startdate><enddate>199502</enddate><creator>Nooney, J.M.</creator><creator>Feltz, A.</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>199502</creationdate><title>Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells</title><author>Nooney, J.M. ; Feltz, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5078-a3befac735ad43a0a18552885babadd7eb8a5928b9370e5eebcc615f96eef8013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Acetylcholine - pharmacology</topic><topic>Animals</topic><topic>Antihypertensive agents</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Benzodiazepines - pharmacology</topic><topic>Benzothiadiazines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Bungarotoxins - pharmacology</topic><topic>Cardiovascular system</topic><topic>Cattle</topic><topic>Cells, Cultured</topic><topic>chromaffin cells</topic><topic>Chromaffin System - cytology</topic><topic>Chromaffin System - drug effects</topic><topic>Chromaffin System - metabolism</topic><topic>Cyclothiazide</topic><topic>desensitization</topic><topic>Dimethylphenylpiperazinium Iodide - pharmacology</topic><topic>Diuretics</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Interactions</topic><topic>Drug Synergism</topic><topic>GYKI 53655</topic><topic>Medical sciences</topic><topic>Neurons - cytology</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Nicotinic Antagonists</topic><topic>nicotinic receptor</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, AMPA - drug effects</topic><topic>Receptors, AMPA - metabolism</topic><topic>Receptors, Nicotinic - drug effects</topic><topic>Receptors, Nicotinic - metabolism</topic><topic>Sodium Chloride Symporter Inhibitors - pharmacology</topic><topic>α‐bungarotoxin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nooney, J.M.</creatorcontrib><creatorcontrib>Feltz, A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nooney, J.M.</au><au>Feltz, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>1995-02</date><risdate>1995</risdate><volume>114</volume><issue>3</issue><spage>648</spage><epage>655</epage><pages>648-655</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><coden>BJPCBM</coden><abstract>1 The desensitizing acetylcholine (ACh) response of bovine chromaffin cells maintained in culture was examined using rapid agonist applications (of 2 s duration) which imposed nominal drug concentrations within 50 ms. This study was aimed, firstly, at identifying which of the α3, α4 and α7 subunits known to be present in these cells is predominant in the ACh‐evoked response and secondly, on the effects on these neuronal nicotinic ACh receptors (AChR) of cyclothiazide (CT), an agent acting as a modulator of a gating desensitization site on other ligand‐gated channels. 2 Locally applied 100 μm ACh evoked peak currents (IAch) of −1.5 ± 0.1 nA (n = 83) at a holding potential of −60 mV. The ACh dose‐response curve yielded an estimated EC50 of 60 μm. This current was not sustained but desensitized during the application period; it displayed strong inward rectification, but desensitized equally whether the evoked current was inward or outward going. The latter observation excludes α4 as a major contributor to the recorded current. Because the response was almost insensitive to a 1 μm α‐bungarotoxin pretreatment (IACg = −12 ± 0.1 nA; n = 6), and because 1, 1‐dimethyl‐4‐phenylpiperazinium (DMPP) works as a potent agonist (peak current = −1.9 nA, n = 2 for 100 μm DMPP), the α7 subunit is also a minor contributor to the response. Taken together, these observations suggest a dominant α3 type of response. 3 Triple exponential fits were used to describe the characteristics of the ACh‐evoked currents; one component to fit the rising phase, with 2 components to describe the decay phase. The decay times were 100 ms and 4 s for the fast and slow components respectively. The rate of the slow decay component increased systematically with recording time, approximately doubling from its initial value within 20–40 min. Furthermore there was a gradual rundown of the response, seen first as a loss of the late component of the current, measured at 2 s, with the peak current amplitude decreasing later in the recording. 4 CT, when coapplied with ACh, produced a dose‐dependent inhibition of the ACh‐evoked peak current. The effect showed little voltage‐dependency with 100 μm CT producing 46 ± 5% (s.d.; n = 3) and 47 ± 8% (s.d.; n = 7) inhibition at −100 and −60 mV respectively. At +60 mV, inhibition was estimated to be 26 ± 7% (s.d.; n = 3). 5 After pre‐exposure of the cells to CT by bath application, 10 and 30 μm CT produced poorly reversible 20 ± 9% (n = 7) and 42 ± 5% (n = 4) inhibitions of the peak current respectively. There were no discernible effects on the fitted decay constants at any CT concentration tested, although an increased inhibitory effect of CT was observed at higher concentrations (100 μm) on the amplitude of the late component measured at 2 s. 6 Similar effects were observed in conditions chosen to isolate the α3 type of receptor: namely when using DMPP as an agonist, or after α‐bungarotoxin pretreatment. 7 The 2,3‐benzodiazepine, GYKI 53655, is known to antagonize the action of CT on AMPA receptors. Coapplication of 50 μm GYKI 53655 with ACh (100 μm) produced a 29 ± 4% inhibition of the peak ACh‐evoked current and 44 ± 6% inhibition of its amplitude at 2 s (n = 4). This response was fully reversible. Brief applications of both CT (100 μm) and GYKI 53655 (50 μm) with ACh via the microperfusion system produced a fully reversible inhibition that was not significantly different from the values obtained with either CT or GYKI 53655 alone, with 37 ± 6% inhibition of peak and 61 ± 9% inhibition of the amplitude at 2 s (n = 3). 8 The results obtained suggest that the CT effect is to impede recovery from a slow desensitization, with a more pronounced effect with longer CT applications. Globally, CT favours the ‘rundown state’ of the neuronal nicotinic AChR.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>7735691</pmid><doi>10.1111/j.1476-5381.1995.tb17188.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 1995-02, Vol.114 (3), p.648-655
issn 0007-1188
1476-5381
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1510031
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Acetylcholine - pharmacology
Animals
Antihypertensive agents
Antihypertensive Agents - pharmacology
Benzodiazepines - pharmacology
Benzothiadiazines - pharmacology
Biological and medical sciences
Bungarotoxins - pharmacology
Cardiovascular system
Cattle
Cells, Cultured
chromaffin cells
Chromaffin System - cytology
Chromaffin System - drug effects
Chromaffin System - metabolism
Cyclothiazide
desensitization
Dimethylphenylpiperazinium Iodide - pharmacology
Diuretics
Dose-Response Relationship, Drug
Drug Interactions
Drug Synergism
GYKI 53655
Medical sciences
Neurons - cytology
Neurons - drug effects
Neurons - metabolism
Nicotinic Antagonists
nicotinic receptor
Pharmacology. Drug treatments
Receptors, AMPA - drug effects
Receptors, AMPA - metabolism
Receptors, Nicotinic - drug effects
Receptors, Nicotinic - metabolism
Sodium Chloride Symporter Inhibitors - pharmacology
α‐bungarotoxin
title Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T18%3A14%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20by%20cyclothiazide%20of%20neuronal%20nicotinic%20responses%20in%20bovine%20chromaffin%20cells&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Nooney,%20J.M.&rft.date=1995-02&rft.volume=114&rft.issue=3&rft.spage=648&rft.epage=655&rft.pages=648-655&rft.issn=0007-1188&rft.eissn=1476-5381&rft.coden=BJPCBM&rft_id=info:doi/10.1111/j.1476-5381.1995.tb17188.x&rft_dat=%3Cwiley_pubme%3EBPH17188%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7735691&rfr_iscdi=true